Barclays
WHWK

Barclays’s Whitehawk Therapeutics WHWK Stock Holding History

Barclays’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.23K Buy
+647
New +$2.03K ﹤0.01% 4841
2024
Q3 		– Sell
-8
Closed -$11 – 5533
2024
Q2 		$11 Sell
8
-11,348
-100% -$21K ﹤0.01% 4789
2024
Q1 		$26.6K Sell
11,356
-10,905
-49% -$21K ﹤0.01% 4722
2023
Q4 		$45K Buy
22,261
+19,434
+687% +$81.5K ﹤0.01% 4790
2023
Q3 		$13.7K Sell
2,827
-401
-12% -$2.33K ﹤0.01% 4250
2023
Q2 		$22.1K Sell
3,228
-4,088
-56% -$31.8K ﹤0.01% 4117
2023
Q1 		$53K Buy
7,316
+3,428
+88% +$36.6K ﹤0.01% 4429
2022
Q4 		$49.9K Buy
3,888
+3,274
+533% +$42.7K ﹤0.01% 4553
2022
Q3 		$9K Sell
614
-326
-35% -$4.28K ﹤0.01% 4368
2022
Q2 		$12K Buy
+940
New +$14K ﹤0.01% 4581
2021
Q2 		– Sell
-777
Closed -$15K – 5118
2021
Q1 		$15K Buy
+777
New +$17.9K ﹤0.01% 4407

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Barclays's WHWK Position: Q1 2026 in Review

Barclays opened a new position in Whitehawk Therapeutics (WHWK) in Q1 2026: 647 shares worth $2.23K. The stake represents ﹤0.01% of the portfolio and ranks #4841 among its holdings. This is a return to the name: Barclays previously reported a position in WHWK as recently as Q2 2024.

Barclays first reported a position in WHWK in Q1 2021 and has held it in 11 quarters since. The position peaked at $53K in Q1 2023. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Barclays held 647 shares of Whitehawk Therapeutics worth $2.23K as of Q1 2026.
  • Whitehawk Therapeutics was a new Barclays position in Q1 2026.
  • Whitehawk Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4841 holding.
  • Barclays first reported a position in Whitehawk Therapeutics in Q1 2021 and has held it in 11 quarters since.
  • Barclays's Whitehawk Therapeutics position peaked at $53K in Q1 2023.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.